Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics Post published:March 28, 2023 Post category:Press Release
Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences Post published:March 14, 2023 Post category:Press Release
Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership Post published:March 6, 2023 Post category:Press Release
Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs Post published:February 2, 2023 Post category:Press Release
Mindset Pharma to Participate in Upcoming Conferences in December 2022 Post published:December 6, 2022 Post category:Press Release
Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences Post published:October 28, 2022 Post category:Press Release
Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio Post published:October 6, 2022 Post category:Press Release
Mindset Pharma Provides Strategic Intellectual Property License to Cybin Post published:September 28, 2022 Post category:Press Release
Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014 Post published:September 14, 2022 Post category:Press Release
Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries Post published:September 7, 2022 Post category:Press Release